• Biomea Fusion

  Participated · Series A · Jan 2021

  Biomea Fusion focuses on a platform of irreversible inhibitors aimed at genomically defined drivers of tumor growth across hematologic and solid tumors. Its lead program is an irreversible menin inhibitor that targets the menin-MLL protein-protein interaction and is in IND-enabling studies. The company plans to enter the clinic with the menin program in the second half of 2021 to generate first-in-human data in patients with liquid and solid tumors. Proceeds from the recent financing will also support two additional irreversible preclinical programs through IND-enabling studies. Biomea intends to expand its core research team to enhance preclinical and clinical capabilities. The company states its mission is to deliver targeted, potentially durable therapies for cancer patients with defined genetic alterations.

• Lyra Therapeutics

  Participated · Series C · Jan 2020

  Lyra Therapeutics is a clinical-stage company developing integrated drug and delivery solutions for localized treatment of ear, nose and throat diseases using its proprietary XTreo platform. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for brief, in‑office administration to deliver up to six months of continuous mometasone furoate therapy to the sinonasal passages. LYR-210 is being developed for surgically‑naïve chronic rhinosinusitis (CRS) patients and is in an ongoing Phase 2 trial; LYR-210 met its primary safety endpoint in Phase 1 and showed clinically meaningful improvement in SNOT-22 scores through week 25. LYR-220 is intended for post‑surgical CRS patients with enlarged nasal cavities who continue to require treatment. The company plans to use recent financing proceeds to advance LYR-210 and LYR-220 and for general corporate purposes. Lyra is also exploring additional applications of its XTreo platform beyond CRS. Lyra Therapeutics is a clinical-stage biotech developing medicines that target ear, nose and throat (ENT) diseases using a proprietary transmucosal therapeutic system. Its lead product, LYR-210, is a biodegradable, physician-administered implant that delivers an approved steroid (mometasone furoate) directly into sinonasal tissues for up to six months. In Phase 1 testing LYR-210 was reported as safe, well-tolerated and showed significant improvements in clinical outcomes in chronic rhinosinusitis (CRS) patients, including those with and without nasal polyps. The company plans to advance LYR-210 into a Phase 2 study for CRS and to apply its polymeric matrix platform to other ENT indications. Lyra recently completed a $29.5 million Series B equity financing to fund the planned Phase 2 and further development activities. The company changed its name from 480 Biomedical to Lyra Therapeutics and is located in the Boston/Watertown, Massachusetts biotech region.

No current team members are available.